Adaptimmune Named as One of “Fierce 15” Biotech Companies of 2014
News Sep 23, 2014
Adaptimmune has announced that it has been named by FierceBiotech as one of 2014’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.
Adaptimmune is focused on the use of T-cell therapy to treat cancer and infectious disease. Using its unique T-cell receptor (TCR) engineering technology, the company has created TCRs which are deployed to target the cancer testis antigen, NY-ESO-1, as well as other targets.
Adaptimmune is running trials across the United States in multiple myeloma, melanoma, sarcoma and ovarian cancer and in June announced a strategic collaboration and licensing agreement with GlaxoSmithKline.
“Adaptimmune CEO James Noble has endured plenty of ups and downs over the years, but GSK’s recent deal puts the U.K. biotech at center stage on TCRs, a hot field in the oncology arena,” says John Carroll, editor of FierceBiotech. “We’ve watched the progress of their sister company - Immunocore - and now we’ll keep a close eye on Adaptimmune’s progress in the clinic.”
James Noble, Chief Executive Officer of Adaptimmune, commented: “We are delighted to be listed by FierceBiotech among the top private biotech firms globally. This award recognizes years of hard work by a dedicated and highly skilled team to develop our technology, culminating in the completion of a major partnership deal with GSK this summer.”
The Fierce 15 celebrates the spirit of being “fierce” - championing innovation and creativity, even in the face of intense competition. This is FierceBiotech’s twelfth annual Fierce 15 selection. A complete list of “Fierce 15” companies can be found online at www.fiercebiotech.com/fierce15.
An internationally recognized daily report reaching a network of over 270,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with an authoritative analysis of the day's top stories.
Every year FierceBiotech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.
Targeted Drug Could be Used to Treat Advanced Cancers Located Anywhere in the BodyNews
A new targeted drug could be used to treat a small number of advanced cancers no matter where they grow in the body.READ MORE
Human Malaria Parasites Grown for the First Time in Dormant FormNews
One of the biggest obstacles to eradicating malaria is a dormant form of the parasite which is resistant to most antimalarial drugs and can reawaken years later, causing disease relapse. Researchers have shown they can grow the dormant parasite in engineered human liver tissue for several weeks, allowing them to closely study how the parasite becomes dormant, what vulnerabilities it may have, and how it springs back to life.READ MORE
Gut Bacteria Latest Ally in Fight Against SepsisNews
Sepsis occurs when the body's response to the spread of bacteria or toxins to the bloodstream damages tissues and organs. The fight against sepsis could get a helping hand from a surprising source: gut bacteria. Researchers found that giving mice particular microbes increased blood levels of immunoglobulin A (IgA) antibodies, which protected against the kind of widespread bacterial invasion that leads to sepsis.READ MORE